10-Q Filing

SOLENO THERAPEUTICS INC CIK: 1484565 Q2 2023

Filing Information

Form Type	10-Q
Accession Number	`0000950170-23-039934`
Period End Date	20230630
Filing Date	20230808
Fiscal Year	2023
Fiscal Period	Q2
XBRL Instance	slno-20230630_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 72 Income Statement 63 Cash Flow Statement 50 Stockholders Equity 34

Balance Sheet 72 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	8.16M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	9.14M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$19.37M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	8.16M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	9.14M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$14.60M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.13M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.04M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$20.50M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$15.65M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$19.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$26.00K	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$131.00K	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$541.00K	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$9.72M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$10.69M	USD	Point-in-time
Other long-term assets	`OtherAssetsNoncurrent`	$165.00K	USD	Point-in-time
Total assets	`Assets`	$30.94M	USD	Point-in-time
Total assets	`Assets`	$26.50M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.78M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$3.44M	USD	Point-in-time
Accrued compensation	`EmployeeRelatedLiabilitiesCurrent`	$1.17M	USD	Point-in-time
Accrued compensation	`EmployeeRelatedLiabilitiesCurrent`	$1.68M	USD	Point-in-time
Accrued clinical trial site costs	`AccruedClinicalTrialCostsCurrent`	$3.22M	USD	Point-in-time
Accrued clinical trial site costs	`AccruedClinicalTrialCostsCurrent`	$3.47M	USD	Point-in-time
Operating lease liabilities - current	`OperatingLeaseLiabilityCurrent`	$212.00K	USD	Point-in-time
Operating lease liabilities - current	`OperatingLeaseLiabilityCurrent`	$155.00K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$484.00K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$513.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$7.31M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$8.80M	USD	Point-in-time
Operating lease liabilities - noncurrent	`OperatingLeaseLiabilityNoncurrent`	$273.00K	USD	Point-in-time
Contingent liability for Essentialis purchase price	`AssetAcquisitionContingentConsiderationLiabilityNoncurrent`	$9.45M	USD	Point-in-time
Contingent liability for Essentialis purchase price	`AssetAcquisitionContingentConsiderationLiabilityNoncurrent`	$8.84M	USD	Point-in-time
Total liabilities	`Liabilities`	$18.52M	USD	Point-in-time
Total liabilities	`Liabilities`	$16.15M	USD	Point-in-time
Commitments and contingencies (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $0.001 par value, 100,000,000 shares authorized, 9,141,185 and 8,159,382 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively	`CommonStockValue`	$10.00K	USD	Point-in-time
Common stock, $0.001 par value, 100,000,000 shares authorized, 9,141,185 and 8,159,382 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively	`CommonStockValue`	$8.00K	USD	Point-in-time
Additional paid-in-capital	`AdditionalPaidInCapitalCommonStock`	$266.67M	USD	Point-in-time
Additional paid-in-capital	`AdditionalPaidInCapitalCommonStock`	$247.76M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-237.42M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-254.25M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	-	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	-	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$12.43M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$26.46M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$20.31M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$2.64M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$17.79M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$10.35M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$30.94M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$26.50M	USD	Point-in-time

Income Statement 63 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$3.70M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$5.14M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$7.68M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$10.46M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$5.11M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$3.17M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$6.02M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$2.47M	USD	1 Quarter
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$612.00K	USD	2 Qtrs
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$313.00K	USD	1 Quarter
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$-242.00K	USD	2 Qtrs
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$616.00K	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$17.09M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$12.55M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$8.62M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$6.78M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-12.55M	USD	2 Qtrs
Operating loss	`OperatingIncomeLoss`	$-6.78M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-17.09M	USD	2 Qtrs
Operating loss	`OperatingIncomeLoss`	$-8.62M	USD	1 Quarter
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$-1.00K	USD	1 Quarter
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$-29.00K	USD	2 Qtrs
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$-2.00K	USD	1 Quarter
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$-1.00K	USD	2 Qtrs
Interest income	`OtherNonoperatingIncomeExpense`	$74.00K	USD	2 Qtrs
Interest income	`OtherNonoperatingIncomeExpense`	$52.00K	USD	1 Quarter
Interest income	`OtherNonoperatingIncomeExpense`	$147.00K	USD	1 Quarter
Interest income	`OtherNonoperatingIncomeExpense`	$260.00K	USD	2 Qtrs
Total other income	`NonoperatingIncomeExpense`	$261.00K	USD	2 Qtrs
Total other income	`NonoperatingIncomeExpense`	$54.00K	USD	1 Quarter
Total other income	`NonoperatingIncomeExpense`	$103.00K	USD	2 Qtrs
Total other income	`NonoperatingIncomeExpense`	$148.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-12.45M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-16.83M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-8.36M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-6.72M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-8.47M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-5.72M	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-2.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$16.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.00K	USD	2 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-16.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$1.00K	USD	1 Quarter
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-16.83M	USD	2 Qtrs
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-12.45M	USD	2 Qtrs
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-6.72M	USD	1 Quarter
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-8.49M	USD	1 Quarter
Net loss per common share basic	`EarningsPerShareBasic`	$-1.69	USD	2 Qtrs
Net loss per common share basic	`EarningsPerShareBasic`	$-0.81	USD	1 Quarter
Net loss per common share basic	`EarningsPerShareBasic`	$-1.69	USD	2 Qtrs
Net loss per common share basic	`EarningsPerShareBasic`	$-0.72	USD	1 Quarter
Net loss per common share diluted	`EarningsPerShareDiluted`	$-1.69	USD	2 Qtrs
Net loss per common share diluted	`EarningsPerShareDiluted`	$-1.69	USD	2 Qtrs
Net loss per common share diluted	`EarningsPerShareDiluted`	$-0.72	USD	1 Quarter
Net loss per common share diluted	`EarningsPerShareDiluted`	$-0.81	USD	1 Quarter
Weighted-average common shares outstanding used to calculate basic net loss per common share	`WeightedAverageNumberOfSharesOutstandingBasic`	10.42M	shares	1 Quarter
Weighted-average common shares outstanding used to calculate basic net loss per common share	`WeightedAverageNumberOfSharesOutstandingBasic`	9.34M	shares	1 Quarter
Weighted-average common shares outstanding used to calculate basic net loss per common share	`WeightedAverageNumberOfSharesOutstandingBasic`	9.94M	shares	2 Qtrs
Weighted-average common shares outstanding used to calculate basic net loss per common share	`WeightedAverageNumberOfSharesOutstandingBasic`	7.35M	shares	2 Qtrs
Weighted-average common shares outstanding used to calculate diluted net loss per common share	`WeightedAverageNumberOfDilutedSharesOutstanding`	10.42M	shares	1 Quarter
Weighted-average common shares outstanding used to calculate diluted net loss per common share	`WeightedAverageNumberOfDilutedSharesOutstanding`	9.94M	shares	2 Qtrs
Weighted-average common shares outstanding used to calculate diluted net loss per common share	`WeightedAverageNumberOfDilutedSharesOutstanding`	7.35M	shares	2 Qtrs
Weighted-average common shares outstanding used to calculate diluted net loss per common share	`WeightedAverageNumberOfDilutedSharesOutstanding`	9.34M	shares	1 Quarter

Cash Flow Statement 50 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-12.45M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-16.83M	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$984.00K	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$979.00K	USD	2 Qtrs
Non-cash lease expense	`NoncashLeaseExpense`	$142.00K	USD	2 Qtrs
Non-cash lease expense	`NoncashLeaseExpense`	$187.00K	USD	2 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$1.22M	USD	2 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$1.83M	USD	2 Qtrs
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$-1.00K	USD	1 Quarter
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$-29.00K	USD	2 Qtrs
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$-2.00K	USD	1 Quarter
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$-1.00K	USD	2 Qtrs
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$612.00K	USD	2 Qtrs
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$313.00K	USD	1 Quarter
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$-242.00K	USD	2 Qtrs
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$616.00K	USD	1 Quarter
Other non-cash reconciling items	`OtherNonCashReconcilingItems`	$-1.00K	USD	2 Qtrs
Prepaid expenses, other current assets and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$290.00K	USD	2 Qtrs
Prepaid expenses, other current assets and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-334.00K	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$1.68M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-848.00K	USD	2 Qtrs
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$-510.00K	USD	2 Qtrs
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$204.00K	USD	2 Qtrs
Accrued clinical trial site costs	`IncreaseDecreaseInAccruedClinicalTrialSiteCosts`	$244.00K	USD	2 Qtrs
Accrued clinical trial site costs	`IncreaseDecreaseInAccruedClinicalTrialSiteCosts`	$-264.00K	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-120.00K	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-227.00K	USD	2 Qtrs
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$92.00K	USD	2 Qtrs
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$29.00K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-12.29M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-10.98M	USD	2 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$7.00K	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-7.00K	USD	2 Qtrs
Proceeds from sale of common stock and common stock warrants, net of costs	`ProceedsFromSaleOfCommonStockAndCommonStockWarrantsNetOfCosts`	$17.06M	USD	2 Qtrs
Proceeds from sale of common stock and pre-funded warrants, net of costs	`ProceedsFromSaleOfCommonStockAndPreFundedWarrantsNetOfCosts`	$13.77M	USD	2 Qtrs
Tax withholding payments for net share-settled equity awards	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$16.00K	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$13.75M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$17.06M	USD	2 Qtrs
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$2.76M	USD	2 Qtrs
Net increase in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$4.77M	USD	2 Qtrs
Cash and cash equivalents, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$21.30M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$24.07M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$14.60M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$19.37M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$21.30M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$24.07M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$14.60M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$19.37M	USD	Point-in-time
Operating lease right-of-use assets obtained in exchange for operating lease obligations	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$597.00K	USD	2 Qtrs
Unpaid financing costs included in accounts payable	`UnpaidCostsForIssuingCommonStockAndPreFundedWarrants`	$14.00K	USD	2 Qtrs

Stockholders Equity 34 line items

Line Item	Tag	Value	Unit	Period
Less transaction costs	`PaymentsOfStockIssuanceCosts`	$1.03M	USD	1 Quarter
Balances at beginning	`StockholdersEquity`	$12.43M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$26.46M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$20.31M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$2.64M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$17.79M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$10.35M	USD	Point-in-time
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$1.20M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$495.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$571.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$464.00K	USD	1 Quarter
Issuance of common stock warrants, net of issuance costs	`AdjustmentsToAdditionalPaidInCapitalWarrantIssued`	$9.97M	USD	1 Quarter
Issuance of restricted stock units under equity incentive plan	`IssuanceOfRestrictedStockUnitsValueAndOptionExercisesUnderEquityIncentivePlan`	$180.00K	USD	1 Quarter
Issuance of restricted stock units under equity incentive plan	`IssuanceOfRestrictedStockUnitsValueAndOptionExercisesUnderEquityIncentivePlan`	$136.00K	USD	1 Quarter
Tax withholding payments for net share-settled equity awards	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$16.00K	USD	1 Quarter
Sale of common stock\pre-funded warrants in public offering, net of costs	`StockIssuedDuringPeriodValueNewIssues`	$7.10M	USD	1 Quarter
Sale of common stock\pre-funded warrants in public offering, net of costs	`StockIssuedDuringPeriodValueNewIssues`	$13.77M	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-2.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$16.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.00K	USD	2 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-16.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$1.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-12.45M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-16.83M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-8.36M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-6.72M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-8.47M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-5.72M	USD	1 Quarter
Balances at ending	`StockholdersEquity`	$12.43M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$26.46M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$20.31M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$2.64M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$17.79M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$10.35M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.